Who’s in the Room (and Who’s Not?)

• Which roles are currently involved in evaluating analyzer replacements or upgrades for your lab? Options: Lab Director, Laboratory Operations Manager, Clinical/Medical Director, Procurement/SSCM, Finance/CFO, IT/LIS, Quality/Compliance (CAP/CLIA), Nursing/Clinical stakeholder, Facilities/Engineering, Other
• Please list the name, title, and best contact method for each person who is actively participating in this decision.
• Which single person or role holds the formal budget authority for this purchase? Options: Capital Budget Owner (CFO/Controller), Departmental Budget Owner (Lab Manager), Procurement Office, Shared/Cost Center Model, Leasing/Finance partner decides, Other
• Who has ultimate sign-off authority for equipment purchases—name or title?
• On a scale from 1–5, how actively engaged are the named stakeholders right now (1 = passive, 5 = driving the decision)? Options: 1, 2, 3, 4, 5

What Would Happen If Nothing Changed?

• If you postponed any analyzer upgrades for another 18 months, what measurable problems would emerge (downtime, costs, backlogs, compliance risk)?
• How frequently are you currently experiencing unscheduled downtime or critical failures that disrupt workflows? Options: Daily, Weekly, Monthly, Quarterly, Rarely/Never
• Which stakeholder(s) would experience the biggest operational or financial pain from that ongoing status quo? Options: Lab Director, Operations Manager, Procurement/Finance, Clinical leadership, Quality/Compliance, IT/LIS, Other
• Can you share a recent example (date and impact) when instrument issues caused clinician delays, overtime, or patient-care risk?
• What is your best estimate of the additional cost (staff overtime, send-outs, reagent waste) tied to current equipment issues over the past 12 months? Options: <$10k, $10k–$50k, $50k–$150k, $150k–$500k, >$500k, Unsure

Who Really Cares About Uptime, Cost, or Compliance?

• Which individual or function would lose the most credibility if turnaround times slipped or results were delayed? Options: Lab Director, Operations Manager, Clinical/Medical Director, Nursing leadership, Hospital Administration, Other
• For the Lab Director: what specific targets would feel like success (e.g., uptime %, TAT median, cost-per-test target)?
• For the Operations Manager: what recurring frustrations should a new solution eliminate (examples: frequent re-calibrations, manual sample moves, staffing spikes)?
• For Procurement/Finance: what financial KPIs must the purchase meet (payback months, NPV threshold, TCO horizon)? Options: <12 months payback, 12–24 months, 24–36 months, 36+ months, TCO over 5 years, Other
• For Quality/Compliance: what regulatory or documentation deliverables are non-negotiable for acceptance? Options: Validation protocol (IQ/OQ/PQ), Traceable QC records, CAP/CLIA audit readiness, Material safety documentation, Other

Where Does Money Come From — And Who Holds the Keys?

• Which funding source will primarily pay for this acquisition if approved? Options: Capital budget (one-time), Operating budget (leasing/consumables), Internal reallocation, Grant or philanthropy, Vendor financing/managed service, Unsure/Other
• When is the next formal capital approval cycle or board review where this could be approved? Options: Within 30 days, 30–60 days, 60–90 days, Quarterly cycle (next quarter), Fiscal year planning (3–9 months), Longer than 9 months, Unsure
• Are there competing capital projects that would likely compete for the same funds this cycle? Options: Yes — several, Yes — one primary competitor, No significant competitors, Unsure
• How flexible is the budget owner if evidence shows immediate clinical risk—would funds be reprioritized? Options: Highly flexible, Somewhat flexible with justification, Rigid — must wait cycle, Depends on executive sponsor
• If you have a target payback period or ROI metric, please specify the number or formula used for decision-making.

Hidden Votes: Politics, Pet Projects, and Quiet No's

• Who is likely to quietly oppose this change, and why might they say no even if the numbers look good?
• Are there existing vendor agreements or preferred-vendor relationships that could limit your ability to switch platforms? Options: Exclusive reagent contract, Preferred supplier list, Maintenance agreement in place, No binding agreements, Unsure
• Has your team attempted a major vendor change in the last 3 years? If yes, what stopped it? Options: Budget constraints, Internal politics, Vendor pushback, Timeline conflicts, Other, No attempts
• What would ease internal resistance—examples: pilot data, clinician testimonials, vendor-funded validation, or guaranteed uptime? Options: Pilot study, Financial guarantee, Case studies/references, Service level guarantees, Training commitments, Other
• Who on your team should we meet next to neutralize opposition or build consensus (name and role)?

Timing Is Everything — What’s the True Deadline?

• If the project does not reach procurement approval by your target date, what operational or financial consequences do you anticipate?
• Select the realistic target date for contract signature or PO issue. Options: Immediately (within 14 days), 30 days, 60 days, 90 days, Within this quarter, Next fiscal year
• What internal milestones must be met before budget release (e.g., business case, ROI model, pilot completion, executive briefing)? Options: Business case approval, ROI model sign-off, Clinical pilot, Validation plan approved, Executive sponsor endorsement, Other
• Are there external deadlines (lease end, contract expiry with current vendor, accreditation event) that create a hard go-live date? Options: Lease/service contract expiry, Regulatory/accreditation deadline, Seasonal volume surge, None, Other
• How firm is your timeline in practice: hard (cannot move), negotiable with justification, or exploratory? Options: Hard, Negotiable with strong justification, Aspirational/exploratory, Unsure

How Will You Know We’ve Gotten It Right?

• For each key stakeholder, what are 2–3 measurable outcomes that will make them say ‘this was worth it’?
• Which objective metrics will be part of your vendor selection scorecard? Options: Uptime %, Median TAT, Cost-per-test, Service response time, Parts availability, Menu breadth, Integration capability, Other
• What acceptance tests or performance thresholds must be met during validation before payment/closeout? Options: Parallel testing results, Uptime demonstration, TAT targets met, QC stability, LIS interface validated, Other
• Who will sign the final acceptance certificate, and what evidence will they expect to see?
• How long after deployment will you evaluate success and what data will you want (30/60/90/180 days)? Options: 30 days, 60 days, 90 days, 180 days, Other

Communication Rhythm — Who Needs What and When?

• If we only sent one weekly update, whose trust would it build—and whose would it undermine?
• Which communication channels do stakeholders prefer for project updates and urgent escalations? Options: Email, Phone call, Scheduled video meeting, Project portal/dashboard, Mobile/text alerts, In-person briefings
• What cadence of reporting do different roles expect (e.g., weekly ops, monthly exec, milestone-driven for procurement)? Options: Weekly, Biweekly, Monthly, Milestone-driven, As needed
• Who should be included on urgent outage or risk escalations (names/titles)?
• Do you have an existing RACI or decision matrix we can align to—if so, please summarize key owners and approvers. Options: Yes - will share, No - can co-create, Partially exists, Unsure

Walk Me Through a Typical Day in Your Lab

• Start simple — describe a typical 24‑hour cycle in your core lab: shifts, sample flow, and the moments you expect systems to be busiest.
• On an average weekday, approximately how many patient samples does your lab process? Options: <1,000, 1,000–5,000, 5,001–20,000, 20,001–50,000, >50,000
• Which analyzer platforms are actively used across your core and reference workflows right now? (select all that apply) Options: Hematology mid‑volume, Hematology high‑throughput, Chemistry mid‑volume, Chemistry high‑throughput, Coagulation analyzers, Urinalysis platforms, Specimen processing automation, Third‑party middleware/LIS, Other
• Which tests or panels account for the highest proportion of your volume, and how are they typically routed between instruments?
• When are your throughput peaks (daily/weekly/monthly), and how long do those peak periods typically last? Options: Morning (06–10), Midday (10–14), Afternoon (14–18), Night (18–06), Start of week, End of month/quarter, Seasonal outbreaks/flu season, Other
• What are the single daily tasks that most consistently consume technician time (e.g., manual sorting, QC, troubleshooting)?

If Machines Could Talk: Where Do They Fail?

• When an analyzer fails unexpectedly, what usually happens first — and how quickly does that ripple through patient care and downstream workflows?
• Which failure modes have you experienced most in the last 12 months? Options: Mechanical jams/transport errors, Optical/read errors, Calibration drift / QC failures, Software crashes / interface down, Reagent depletion or poor reagent quality, Consumable failures (tips, tubes), Operator error, Other
• How often do unscheduled maintenance events occur per instrument on average? Options: Weekly, Monthly, Quarterly, Annually, Less than yearly, Varies widely by instrument
• Tell us about a recent outage: what component failed, how long was the impact, what workaround was used, and what downstream consequences occurred?
• Which root causes do you suspect are underinvestigated (design/aging hardware, training gaps, supply chain, workflow mismatch)? Options: Design / aging hardware, Operator training gaps, Reagent / supply variability, Inadequate preventive maintenance, Integration / LIS errors, Staffing and scheduling, Other

What Feels Fragile Right Now?

• If you had to name the single most fragile part of your testing operation, what would it be — and why does it keep you up at night?
• Where are your single points of failure today — an instrument, a connector, a reagent supply, or a person? Options: Single analyzer handling critical panels, Single LIS/middleware interface, Single reagent vendor, Single trained operator or small team, Physical space constraint, Other
• How constrained is your physical footprint when adding a new analyzer or creating redundancy? Options: Plenty of space, Some reconfiguration needed, Tight — minor changes only, No room without renovation, Unsure / under assessment
• Which spare parts or consumables run out most frequently, and how long does replenishment typically take?
• How confident are you in your contingency plans for analyzer downtime and surge events? Options: Very confident, Somewhat confident, Not confident, We don’t have a plan

Who Really Owns the Risk?

• If a prolonged equipment outage caused missed turnaround targets, who would ultimately be accountable — and what would that accountability look like?
• Which stakeholders are engaged in day‑to‑day analyzer decisions versus capital purchase approvals? Options: Lab director, Operations manager, Biomedical engineering / clinical engineering, Supply chain / procurement, Finance / CFO, IT / LIS team, Clinical stakeholders (physicians), Other
• Who currently signs off on service contracts, reagent agreements, and spare parts budgets?
• What are the reporting and escalation paths for quality events tied to analyzer performance (internal QA, hospital committee, vendor escalation, regulatory reporting)? Options: Internal lab incident reports, Hospital QA/Quality committee, Regulatory reporting (CAP/CLIA/FDA), Supplier/vendor escalation, Combined multi‑channel process, Other
• How do regulatory requirements (CAP, CLIA, FDA) shape who owns risk and which mitigations are non‑negotiable?

How Do You Measure Success in Real Time?

• If you could fix only one KPI immediately — uptime, turnaround time, cost‑per‑test, or analytical quality — which would it be and why? Options: Uptime/availability, Turnaround time (TAT), Cost per test, Analytical quality / error rate, Operator productivity, Other
• Which KPIs do you actively track on dashboards or in daily huddles? (select all that apply) Options: Analyzer uptime (%), TAT by test, Samples processed per hour, Repeat/reject rates, Cost per result, Service response time, Inventory days on hand, QC pass/fail rates, Other
• What systems capture those KPIs today (LIS, middleware, vendor remote monitoring, manual spreadsheets, BI tools)? Options: LIS, Middleware, Vendor remote monitoring/portal, Manual spreadsheets, Business intelligence/dashboard tools, Other
• What KPI thresholds trigger immediate intervention or escalation (give examples and values where possible)?
• Do you have at least six months of historical KPI data available for review? Options: Yes, easily accessible, Yes, but needs aggregation, Limited historical data, No historical tracking

What Would a Day with No Unplanned Downtime Look Like?

• Imagine zero unscheduled stops across your fleet today — what immediate operational and human differences would you notice (workload, stress, clinician feedback)?
• What throughput and TAT targets would make you consider a new system successful in your real workflows?
• What cost‑per‑test or operational savings target would justify replacing or consolidating analyzers in your lab? Options: <5% savings, 5–10% savings, 10–20% savings, >20% savings, Undefined — need vendor help modeling
• What non‑negotiable acceptance criteria would your team require during a pilot (give percentages, time windows, or error thresholds)?
• How would operator workflow, headcount, or training requirements change in that ideal scenario?

Where Are Decisions Stalling?

• What’s the most common reason a capital purchase, service contract, or inventory agreement stalls in your organization? Options: Budget approval, ROI/business case questions, Procurement/contract cycles, Clinical proof of benefit, Space/pre‑install constraints, IT/LIS approvals, Other
• How long is your typical capital approval cycle from proposal to purchase order? Options: <3 months, 3–6 months, 6–12 months, >12 months, Varies greatly by project
• Which ROI or financial metrics does finance require to greenlight analyzer purchases? Options: Payback period, Net present value (NPV), Cost per test reduction, Labor savings, Total cost of ownership (TCO), Other
• Which documents or demonstrations most influence procurement decisions (rank or list what matters most)? Options: Cost model/ROI, On‑site pilot results, SLA/service commitments, Reference site visits, Clinical validation data, Regulatory/compliance evidence, Other
• Who needs to be engaged earlier to remove blockers, and what would help accelerate their buy‑in (data, site visits, vendor references)?

What Would Make You Say Yes?

• If we could guarantee one measurable outcome during a short trial, what outcome would make you sign a multi‑year agreement?
• Which trial format would be most convincing: on‑site pilot, split‑workflow comparison, remote stress test, reference‑lab validation, or hybrid? Options: On‑site pilot, Split‑workflow A/B test, Remote/simulated stress test, Reference lab validation, Hybrid approach
• What minimum pilot duration and sample volume would you require to feel confident in results? Options: 1–2 weeks / limited volume, 4–6 weeks / moderate volume, 2–3 months / near full volume, Other
• What specific success signals must appear in pilot reports for leadership to approve scale‑up (please list thresholds where possible)? Options: Sustained uptime %, TAT improvement, Measured cost savings, Reduced repeat/error rates, Operator satisfaction, Regulatory/validation compliance
• Who would need to sign off at the end of a pilot, and what evidence or deliverables would each approver require?

A Quick Orientation — who are we talking about?

• Who will be the primary point(s) of contact for procurement conversations (name + role)?
• Briefly describe your lab footprint and operating rhythm (tests/week, 24/7 vs days, number of sites in scope).
• Which analyzer families or platforms are explicitly in scope for replacement, refresh, or expansion? Options: Hematology, Chemistry, Coagulation, Urinalysis, Specimen automation, Other / mixed
• What is the single most important outcome you’re hoping procurement will deliver this year? Options: Reduce cost-per-test, Increase throughput, Improve uptime/reliability, Standardize platforms, Shorten TAT for critical assays, Other
• Who else on your team should be part of budget conversations (clinical leads, finance, supply chain, IT)?

What if the budget isn't there — what happens next?

• If your capital request fails this cycle, what will that mean for patient care, throughput, or staffing in the next 12 months?
• Which fiscal deadline(s) govern capital approval in your organization? Options: Current fiscal quarter, End of fiscal year, Start of next fiscal year, Multi-year approval window, Rolling/continuous approvals, Unsure
• How often are capital requests reviewed by the committee that signs off on equipment purchases? Options: Monthly, Quarterly, Twice yearly, Annually, Ad hoc by committee chair
• Tell a recent story: when a previous equipment request failed, what were the reasons given and what changed afterwards?
• When emergency replacement is required, what funding pathway is used (operational reserve, contingency, accelerated CAPEX)? Options: Operational reserve, Contingency fund, Reallocation of existing CAPEX, Short-term lease, Other / varies

Who truly controls the purse strings?

• Who is the named budget owner(s) for this capital line and who are their alternates?
• At what organizational level is the budget held? Options: Department/Service line, Facility/hospital, Health system consolidated, Shared matrix budget, Third-party/partner controlled
• Are internal chargebacks or interdepartmental billing practices part of how you evaluate ROI? Options: Yes, heavily, Partially, Rarely, Not at all, Unsure
• Which of these funding mechanisms are you open to (select all that apply)? Options: Straight purchase (CAPEX), Capital lease, Operating lease / subscription, Vendor financing, Grant / philanthropic funding, Other
• How would you describe procurement’s attitude toward new vendors versus incumbent suppliers? Options: Prefer incumbents, Open to new if validated, Actively seeking best-of-breed, Vendor-neutral policy

If numbers had to sell this — what story would they tell?

• If the CFO looked at one metric and nothing else, which would make them say yes? Options: Net Present Value (NPV), Payback period, Cost-per-test reduction, Total Cost of Ownership (TCO), Uptime / SLA risk reduction, Other
• What minimum ROI, payback window, or cost-per-test improvement has been set as a threshold for this purchase? Options: Payback < 1 year, 1–2 years, 2–3 years, 3–5 years, No formal threshold / case-by-case
• Please list current baseline cost-per-test (or range) for your highest-volume assays and the target reduction you’d expect.
• Who prepares or validates your financial model (internal finance, central analytics, external consultant)? Options: Internal finance, Centralized capital planning, Lab operations with finance review, External consultant, Vendor-supported model
• Would you want the vendor to provide a pre-built ROI/TCO model we can adapt to your numbers? Options: Yes — ready to review, Maybe — we'd like a draft, No — we use our own model

What are the hidden tripwires that have sunk approvals before?

• What non-financial objections (political, clinical trust, vendor risk, space/IT constraints) have derailed projects in the past?
• Which regulatory or accreditation milestones must be met before procurement can complete (CAP, CLIA, state approvals)? Options: CAP, CLIA, State health dept, Local hospital credentialing, IRB/research committee, None required
• Do site constraints (power, HVAC, footprint, LIS connectivity) require separate approvals or capital for upgrades? Options: Yes — separate capital needed, Yes — included in request, No — site is ready, Unsure
• Has concern about reagent supply continuity or single-source dependencies influenced past decisions? Options: Major factor, Minor factor, Not a factor, Unsure
• Describe a past procurement that succeeded despite obstacles — what overcame objections?

Decision rhythms — where are the hard dates and meetings?

• Which single calendar date would force a yes/no decision on this purchase (budget close, fiscal year end, contract expiry)?
• Which committees or approvals must sign off and how often do they meet? Options: Capital committee, Finance committee/CFO, Clinical governance, Supply chain council, Board/trustees, Other
• What lead time does procurement require between final approval and PO issuance? Options: <2 weeks, 2–4 weeks, 1–2 months, 2–3 months, Longer than 3 months
• Are there internal ‘use it or lose it’ spending windows that create urgency? Options: Yes — strong deadline, Occasional, No
• How flexible are your target installation/go-live dates if approval shifts? Options: Fixed — cannot move, Somewhat flexible (weeks), Flexible (months), To be decided

What would make approval frictionless?

• If we could deliver one piece of evidence today that would fast-track approval, what would it be (pilot data, peer reference, guaranteed rebate)?
• Would a short, vendor-funded pilot or proof-of-concept at your site materially change the committee’s view? Options: Yes — high impact, Possibly — helpful, No — unlikely to change, Unsure
• Which contractual terms are showstoppers for your organization (select all that must be met)? Options: Minimum warranty length, Uptime SLA and credits, Parts availability/stocking, Reagent supply guarantees, Flexible payment terms, Data ownership / LIS integration
• Would alternative commercial structures (deferred payment, outcome-based pricing, reagent-consumption agreement) be considered? Options: Yes — willing to discuss, Maybe — depends on terms, No — prefer standard CAPEX
• Who must be included on final procurement documents to avoid last-minute objections (names/roles)?

Commit signals — what are the next concrete moves?

• Based on today’s discussion, what is the single next milestone that would most advance approval (internal review, updated ROI, pilot scheduling)? Options: Internal finance review, Updated ROI model, Pilot scheduling, Procurement RFP, Executive briefing
• What internal materials or approvals should we prepare and share to accelerate your committee review? Options: Detailed ROI/TCO model, Clinical validation plan, Service level proposal, Reference site report, Installation timeline
• How would you like vendor support during your approval cycle (presentation to committee, responding to RFP, onsite pilot assistance)? Options: Committee presentation, Respond to RFP/RFI, Onsite pilot support, Financial term negotiation, All of the above
• Realistically, when should we check back to review an updated approval timeline? Options: Within 1 week, 2 weeks, 1 month, Quarterly, After you update finance
• Is there anything about your procurement culture or past experiences we should know to avoid surprises?

Quick Orientation: Where We’re Starting From

• Which facility and role should we use as the primary contact for deployment planning? Options: Hospital core lab - Laboratory Director, Hospital core lab - Lab Manager/Operations, Reference lab - Lab Manager, Health system - Supply Chain/Procurement, IT/Network Admin, Facilities/Engineering, Quality/Regulatory Lead, Other
• Tell us briefly about your lab’s operating model and busiest hours (e.g., 24/7 core, weekday day shift, weekend peaks). Options: 24/7 core lab, Weekdays + limited weekends, Day shift only (Mon–Fri), Variable/rotating peaks (evenings/nights), Other
• What analyzer platforms and sample handling systems currently constitute your core testing fleet? Options: Our vendor’s systems (list separate below), Mixed vendors / legacy + new, Mostly legacy/out-of-warranty instruments, Small footprint, few analyzers, Other
• Approximately how many reportable results does this site produce per day at typical capacity and at peak?
• What’s the single deployment concern you’d most want us to solve for in the first week of install?

If This Goes Wrong Overnight, What Keeps You Up?

• If the new instrument couldn’t be used tomorrow, what single failure would have the biggest clinical or operational impact? Options: Loss of critical test menu, Network/LIS disconnect, Power failure/no UPS, Reagent delivery disruption, Service response delay, Other
• Which recent incidents (power loss, network outage, delivery delay, service backlog) have caused the most disruption in the past 12 months? Please describe.
• Which utilities or site services do you consider single points of failure for analyzer uptime? Options: Main power (no backup), Backup generator only, Cooling/HVAC, Compressed air, Hospital water/RO, Network connectivity/LIS, None; redundant systems exist, Other
• How quickly does your team need a recoverable workaround (hours/days) before clinical escalation? Options: <4 hours, 4–12 hours, 12–24 hours, 24–72 hours, >72 hours

Power, Air, and Space — Are We Assuming Too Much?

• Do you have dedicated electrical capacity and a recommended circuit for new analyzers, or will we need to schedule new wiring? Options: Dedicated circuit in place, Dedicated circuit available but needs verification, New wiring required, Unsure — facilities must assess
• Is there on-site UPS and/or generator coverage for the proposed instrument location? If yes, what runtime is available on battery/generator? Options: UPS + generator with full coverage, UPS only, Generator only, No backup power, Unsure — need facilities confirmation
• Describe the room environmental controls we should expect (temperature range, humidity, HVAC schedule) and any constraints.
• Are there any load-bearing, doorway, or ceiling access restrictions (e.g., elevators, narrow corridors, cleanroom thresholds) that could complicate delivery and installation? Options: Clear access for standard delivery, Requires elevator reservation, Requires disassembly to pass through doors, Stair-only access, Restricted/sterile area access protocols, Unsure — need site survey
• Are there planned facility projects (construction, HVAC maintenance, electrical upgrades) in the next 90 days that could affect install timing? Options: Yes — construction/renovation, Yes — major HVAC work, Yes — electrical upgrades, No scheduled work, Unsure

Can Your Network Play Nice With Ours?

• Do you have firewall or port policies that typically delay instrument-LIS integration—are we prepared to open HL7/REST ports on an accelerated timeline? Options: We can provision ports quickly, Requires formal change request (~days), Requires CISO approval (~weeks), Strict policy — external connections blocked, Unsure
• Which LIS and middleware products are in use at the site (vendor and version)?
• Do you prefer on-premise HL7 bidirectional connections, secure VPN/managed cloud connectivity, or a middleware-hosted approach for instrument/LIS integration? Options: On-premise HL7 bidirectional, Secure VPN to vendor, Middleware-hosted integration (vendor/mfg), Cloud-native integration, Undecided
• How soon can your IT/network team review and approve port/IP provisioning once we provide requirements? Options: Same day, 1–3 business days, 4–10 business days, >10 business days, Needs escalation
• Please provide primary IT/network contact(s) and preferred method for technical onboarding (email, ticket, scheduled call).

Where Will the Instrument Live and How Will People Use It?

• If the instrument sits in place today, how would it change day-to-day operator workflows and sample flow? What friction do you anticipate?
• What is the proposed room footprint and clearance around the instrument (width x length x clearance), or can you schedule a site diagram upload? Options: Upload available/diagram provided, Can email room dimensions, Need vendor site visit to confirm
• How many operators per shift will be expected to competently run the system at go-live, and what baseline training level do they currently have? Options: 1–2 operators trained, 3–5 operators trained, >5 operators trained, No operators trained yet
• Are there security/access rules (badge access, restricted hours, clinical oversight) that will affect service or delivery teams? Options: Standard badge access, Restricted hours for contractors, Background check required, Sterile/clean area protocols, No special restrictions, Other
• Describe how samples will be routed to/from the instrument (manual tray, conveyor, automation line) and any automation handoffs we must integrate with.

Do You Have the Parts to Win a Race — And the Plan to Stock Them?

• Do you maintain on-site spare parts for current analyzers, and how is that inventory managed (PMA, vendor-owned consignment, ad hoc)? Options: Vendor consignment/MVI, Customer-managed stock, Minimal spares, order as needed, No spare parts policy, Other
• Which categories of spares are mission-critical for your operation to avoid service downtime (e.g., pumps, sensors, power modules)? Please list.
• How do you currently handle reagent stocking and expirations—do you use FIFO, vendor-managed inventory, or just-in-time delivery? Options: FIFO with in-house stock control, Vendor-managed inventory (consignment/Kanban), Just-in-time deliveries, Centralized health system distribution, Other
• What cold-chain or storage constraints exist for reagents (walk-in fridge, limited refrigerator space, dedicated cold room)? Options: Ample fridge/freezer capacity, Limited refrigerated space, No dedicated cold storage, Centralized pharmacy handles cold chain, Other
• How quickly can you accept emergency spare part or reagent deliveries (hours), and do you have preferred courier vendors? Options: <4 hours, 4–12 hours, 12–24 hours, >24 hours, Varies by item

Who Owns What When the Clock Starts Ticking?

• Who is the single on-site owner that will sign installation and operational acceptance on behalf of the lab? Options: Laboratory Director, Lab Manager/Operations, Clinical Lead/Pathologist, Supply Chain/Procurement Lead, Other
• Who are the required stakeholders we should schedule for pre-install signoff (Facilities, IT, Pharmacy, Risk, Infection Control)? Please list names and roles.
• Do you have formal institutional approval steps (capital equipment committee, purchasing, clinical governance) that must complete before installation? If so, which and typical lead times? Options: Capital approval required (weeks), Procurement PO required (days–weeks), Clinical governance review required, No formal approvals, Unsure
• Who will be responsible for coordinating vendor access to site (badging, contractor orientation, insurance certificates)? Options: Facilities/Engineering, Site Procurement, Lab Manager, Vendor handles directly, Other
• Are there union or staffing agreements that affect when vendor engineers can work onsite (shift restrictions, overtime rules)? Options: Yes — strict restrictions, Yes — limited overtime allowed, No union restrictions, Unsure

How Will We Prove It’s Working Before You Trust It?

• What measurable acceptance criteria will you require for go-live (uptime %, TAT, percent concordance with existing method)? Options: Uptime target (%): specify below, TAT improvement target, Analytical concordance thresholds, Throughput targets, Other — specify
• Which regulatory or accreditation requirements must the validation specifically demonstrate compliance with (CAP, CLIA, local regulatory bodies)? Options: CAP, CLIA, State lab regs, ISO/other, Internal hospital QA only, Other
• How long of a parallel testing period do you expect before signing acceptance (e.g., number of days, sample volume)? Options: Single day spot checks, 3–5 days, 1–2 weeks, >2 weeks, By sample volume rather than days (specify)
• Who will be the final signatory on the acceptance report and what format do they prefer (email, signed PDF, LIS entry)? Options: Laboratory Director - signed PDF, Lab Manager - email confirmation, Quality/Regulatory - formal report, Procurement - PO closeout, Other
• Are there local SOPs, method comparison protocols, or IQ/OQ templates you require we follow or map to? Options: Provide our standard templates, Map to your institutional templates, Combine vendor + site SOPs, Unsure — will provide documentation

If the First 90 Days Were Perfect, What Changed?

• What are the top 3 operational KPIs that will prove this deployment is a success (e.g., uptime %, tests/hour, cost-per-test reduction, TAT)? Please rank or list. Options: Uptime (%), Throughput (tests/hour), Turnaround time (TAT), Cost-per-test, Operator touches/assay, Service response time
• What specific targets would make you feel comfortable (numerical targets for uptime, TAT, cost-per-test)?
• How do you prefer to receive operational performance reports post-deployment (daily dashboard, weekly email, monthly review meeting)? Options: Daily dashboard, Weekly summary email, Monthly KPI review meeting, Quarterly business review, Ad hoc on request
• What escalation path should we follow for urgent operational issues after handover (who to call, SLA expectations)?
• Who on your team should be on a 90-day post-implementation review to capture lessons and improvement opportunities? Options: Lab Manager/Operations, Laboratory Director, Quality/Regulatory, IT/Network, Facilities, Supply Chain/Procurement

Let’s Put a Real Plan on a Calendar

• What is your target installation window or committed go-live date? Options: ASAP — within 2 weeks, Within 1 month, 1–2 months, 2–3 months, Quarter+ out
• Are there blackout dates or periods we should avoid for install (e.g., accreditation surveys, major IT change windows, peak holidays)? Please list.
• What lead times do you require for reagent and consumable stocking before install (minimum days of on-site stock)? Options: No minimum — deliver at install, 3–7 days, 7–14 days, >14 days, Vendor-managed stock preferred
• Who will be accountable for approving the final installation schedule and communicating it to internal stakeholders? Options: Lab Manager/Operations, Procurement/Supply Chain, Facilities/Engineering, Vendor project manager, Other
• List any budget or billing constraints that will affect when we can schedule work (PO release, fiscal year close, capital holdbacks).

Getting to Know Your Lab

• Tell us briefly what kind of lab you run and who you serve (hospital core, reference lab, outpatient network, specialty clinic, other). Options: Hospital core lab, Reference lab, Health system with multiple sites, Outpatient/clinic lab, Specialty lab (oncology, molecular, etc.), Other
• What’s your current average daily sample volume and how does it break down across shifts? Options: <500/day, 500–2,000/day, 2,000–10,000/day, 10,000–50,000/day, >50,000/day
• Who is the primary decision owner for lab equipment purchases in your organization? Options: Lab Director/Medical Director, Lab Operations Manager, Supply Chain / Procurement, Finance / CFO, Multi-stakeholder committee, Other
• Which analyzer platforms and automation do you currently operate (list brands/models or 'mixed fleet')? Options: Single-vendor platform, Mixed vendors / multiple platforms, Mostly legacy/aging equipment, Newer high-throughput platform(s), Other
• Describe one recent day that felt 'typical'—what went well and what consumed most of your team's time?
• Which core test menus represent the bulk of your workload (select up to 4)? Options: CBC/hematology, Chemistry/basic metabolic panels, Coagulation, Urinalysis, Immunoassay, Microbiology, Other

Are You Settling for 'Good Enough'?

• If you had to name one worry you’ve quietly accepted as 'just how things are' in your lab, what is it?
• How often do those accepted issues force you to change staffing, defer tests, or delay results? Options: Daily, Several times a week, Weekly, Monthly, Rarely
• When those issues happen, who bears the consequences most often—clinicians, patients, your team, or procurement? Help us understand the human impact. Options: Clinicians, Patients, Lab staff, Procurement/Finance, Multiple groups equally
• Tell a specific story of a day a critical failure or backlog happened—what triggered it and what was the fallout?
• If someone said you could eliminate one persistent pain today, what would you choose and why?

Where the Bottlenecks Hide

• What single constraint most prevents your lab from hitting target turnaround times or throughput goals? Options: Analyzer uptime/failures, Reagent availability, Staffing/skill gaps, Physical space/footprint, Pre-analytical sorting/labeling, LIS/connectivity delays, Other
• How frequently do unscheduled maintenance events interrupt operations, and what is the typical downtime per event? Options: Multiple times/week, Weekly, Monthly, Quarterly, Less than quarterly
• Which parts of your workflow create the most manual touchpoints (sample prep, loading, calibration, QC, reporting)? Options: Sample prep, Loading and batching, Calibration/maintenance, Quality control checks, Result validation/reporting, Specimen sorting
• Are there sample types, test volumes, or testing windows where current analyzers consistently fall short? Describe with examples.
• What workarounds have you tried to bridge bottlenecks and how sustainable have they been?
• If you could measure one thing better to reveal the root cause of delays, what would it be (e.g., mean time to repair, reagent stockouts, queue length)? Options: Mean time to repair (MTTR), Reagent stockout frequency, Queue length by test type, Operator intervention rate, QC failure rate, Other

Money and Momentum: Who Holds the Keys?

• What is the fastest pathway to get capital approved for new lab equipment in your organization—and what usually trips it up?
• Which stakeholders must approve purchases, and which of them do you find hardest to persuade? Options: Lab Director, Operations Manager, Procurement, Finance/CFO, IT, Clinical leadership
• Does your organization require an ROI payback period or specific financial metrics for equipment approvals? If yes, what are they? Options: 3-year payback, 5-year payback, Net present value (NPV) threshold, Internal rate of return (IRR) minimum, No strict ROI requirement, Other
• How flexible is your budget type—capital expenditure (CapEx), operating expense (OpEx), leasing, reagent-as-a-service, or creative financing? Options: CapEx only, OpEx (lease/rental), Reagent-as-a-service, Mixed/negotiable, Unsure
• What timeline drives buying decisions (end of fiscal year, calendar quarter, grant cycle)? Please specify target date(s). Options: Immediate (30 days), Within 3 months, 3–6 months, 6–12 months, 12+ months
• Tell us about a previous procurement that succeeded—what made approval smooth and who championed it?

What Success Actually Looks Like

• If you had to write a one-sentence definition of success for a new analyzer deployment, what would it say?
• Which measurable outcomes would convince you a solution is delivering (select top 3)? Options: Analyzer uptime (%), Turnaround time (TAT), Cost-per-test, Operator interventions per hour, Throughput (samples/hour), QC failure rate, Other
• What minimum uptime and TAT targets are non-negotiable for your lab to accept a new system?
• How would you prefer performance to be demonstrated—pilot study, side-by-side comparator testing, vendor-provided data, or third-party validation? Options: On-site pilot, Side-by-side comparison, Vendor-provided clinical data, Third-party validation/peer-reviewed, Hybrid approach
• Who will sign final acceptance when the system meets those targets, and what documentation do they require?

How New Systems Need to Fit Day-to-Day

• What integration or connectivity must a new system support from day one to avoid disruption? Options: Bidirectional LIS integration, HL7 messaging, Middleware compatibility, Inventory management integration, Network/NMS visibility, Other
• Describe any physical or environmental constraints (power, HVAC, bench/footprint, access routes) that often get overlooked.
• What level of operator involvement do you want—fully automated with minimal touches, semi-automated, or manual-heavy? Options: Fully automated (minimal touches), Semi-automated (periodic operator action), Manual-heavy (operator-run)
• How important is a single-vendor integrated workflow versus best-of-breed components from different suppliers? Options: Prefer single-vendor integrated, Prefer best-of-breed mix, Neutral/open
• What training and handover approach gives your team confidence—train-the-trainer, on-site multi-day sessions, e-learning plus shadowing? Options: On-site multi-day training, Train-the-trainer, E-learning + supervised shadowing, Blended approach
• How do you prefer spare parts, reagents, and support contracts structured (stock on-site, vendor-managed inventory, emergency kits)? Options: Stock on-site, Vendor-managed inventory (VMI), Consignment, Emergency kits + on-call support, Other

Risk, Compliance, and What Keeps You Awake

• When you think about regulatory or inspection risk (CAP/CLIA/other), what single concern worries you most about bringing in new equipment?
• What evidence and documentation do your accrediting bodies expect for validation and acceptance (IQ/OQ/PQ, method comparison, SOP updates)? Options: IQ/OQ/PQ documentation, Method comparison data, Updated SOPs/training records, Risk assessments, All of the above, Other
• How comfortable are you running internal validation vs expecting the vendor to deliver a validated package? Options: We’ll run full internal validation, Prefer vendor-provided validated package, Hybrid: vendor data + local verification, Unsure
• What contingency plans do you have for prolonged downtime (loaner equipment, sample referral, overtime staffing)? Options: Loaner equipment, Sample referral to reference lab, Overtime/temporary staff, Partial manual testing, No formal plan
• How would a third-party audit or inspection change your acceptance criteria for a new system? Options: Raise documentation requirements, Require external validation, No change, Unsure

Decision Tradeoffs: What Would Make You Say Yes?

• What’s the one promise a vendor could make that would most move you toward a purchase decision?
• Rank the following decision levers in order of importance for your next purchase. Options: Uptime guarantees/SLAs, Total cost of ownership (reagent + maintenance), Throughput capacity, Integration ease (LIS), Service response time, Training/support quality
• Would you be open to a time-limited pilot or proof-of-concept in your live workflow? If yes, what would be required to run one? Options: Yes—on-site pilot, Yes—parallel testing, Maybe—depends on logistics, No
• What commercial terms would you need to see to reduce perceived risk (warranty length, service credits, performance guarantees, reagent buy-back)? Options: Extended warranty, Service credits for downtime, Performance SLAs, Reagent buy-back/return, Flexible financing
• Who would be your internal champion and who could block the decision if not convinced?
• If you had to set a go/no-go date for a purchasing decision today, when would it be and why? Options: Immediate (30 days), Within 3 months, 3–6 months, 6–12 months, Longer than 12 months

Next Steps & Practical Commitments

• What data or demonstrations would you want from us next to feel confident moving forward (onsite demo, detailed cost model, reference visits, technical specs)? Options: Onsite demo/pilot, Detailed TCO/cost model, Reference site visits, Technical/spec sheets and validation data, All of the above
• Who else should join our next conversation to avoid delays (names/titles), and what role should each play?
• What does an ideal evaluation timeline look like from your perspective—milestones we should commit to?
• If we could propose one small experiment to prove value quickly, would you consider a parallel-run during a high-volume shift or a weekend pilot? Which do you prefer? Options: Parallel-run during high-volume shift, Weekend pilot, Short-term side-by-side, Prefer not to pilot
• Finally, what would make you feel confident we understand your lab’s reality and are the right partner to solve it?